Tumor (Fig. 5B) and splenic (Fig. 5C) lymphoid DCs, CD69+ NK cells (Fig. 5D) and IFNγ+ CD4+ T cells (Fig. 5E) were significantly increased in CTX-treated tumors compared to controls but there was no further increase in VTX+ CTX-treated tumors compared to CTX alone (Fig. 5B–E). This evidence concerns the gene CD4 and neoplasm.